Trial reportEuropean journal of clinical pharmacology1993
A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia.
Trial report in European journal of clinical pharmacology, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 3 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.The Cochrane database of systematic reviews · 2018Pooled it
- First-line renin-angiotensin system inhibitors vs. other first-line antihypertensive drug classes in hypertensive patients with type 2 diabetes mellitus.Journal of human hypertension · 2018Pooled it
- Differential Metabolic Effects of Beta-Blockers: an Updated Systematic Review of Nebivolol.Current hypertension reports · 2017Pooled it
- Carvedilol modifies antioxidant status of patients with stable angina.Cellular & molecular biology letters · 2008Trial
- Effects of Zofenopril on Arterial Stiffness in Hypertension Patients.Molecular biotechnology · 2025Article
- Cytoprotective Potential of Aged Garlic Extract (AGE) and Its Active Constituent, S-allyl-l-cysteine, in Presence of Carvedilol during Isoproterenol-Induced Myocardial Disturbance and Metabolic Derangements in Rats.Molecules (Basel, Switzerland) · 2021Article
- The effect of fat intake and antihypertensive drug therapy on serum lipid profile: a cross-sectional survey of serum lipids in male and female hypertensives.Molecular and cellular biochemistry · 2010Article
- Metabolic properties of vasodilating beta blockers: management considerations for hypertensive diabetic patients and patients with the metabolic syndrome.Journal of clinical hypertension (Greenwich, Conn.) · 2004Review
- Beta blocker therapy after acute myocardial infarction in patients with heart failure and systolic dysfunction.Heart failure reviews · 2004Review
- Beta-blockers in the management of hypertension in patients with type 2 diabetes mellitus: is there a role?Drugs · 2001Review
- Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.Drugs · 1997Review
- A risk-benefit assessment of carvedilol in the treatment of cardiovascular disorders.Drug safety · 1994Review
- Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.Drugs · 1993Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have studied 250 patients with mild to moderate essential hypertension (diastolic blood pressure 95-114 mmHg) and dyslipidaemia (high-density lipoprotein cholesterol (HDL-C) below 1.03 mmol.l-1, total cholesterol 5.17-9.05 mmol.l-1, and triglycerides 2.26-5.64 mmol.l-1) in a controlled double-blind, multicentre, parallel group trial. The patients took a fat-modified diet. After a 4-week placebo period, patients who continued to fulfil the selection criteria were randomly allocated to treatment with either carvedilol (a vasodilating beta-blocker) 25-50 mg o.d. (n = 116) or captopril (an ACE inhibitor) 25-50 mg o.d. (n = 117) for 6 months. In both groups there were favourable effects on the serum lipids. The relative changes (medians) in the carvedilol and captopril group were respectively: increase in HDL-C by 11% and 8%, decrease in total cholesterol by 11% and 10%, in low-density lipoprotein cholesterol by 16% and 12%, and in triglycerides by 13% and 14%. Equivalence of the two treatments was confirmed for the target variable change in HDL-C at a significance level of 5%. Reductions in supine systolic/diastolic blood pressures were comparable in the two groups (carvedilol: 23/19 mmHg, captopril: 20/18 mmHg). The improvement in lipid metabolism in patients treated with carvedilol is probably due to its alpha 1-blocking properties.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.